Key Highlights

  • Third-quarter Revenue was USD 123.0 million against USD 83.5 million, an increase of about 47.2% (calculated), as test volumes and reimbursement both improved.
  • Net income was USD 17.4 million against USD 5.7 million, and Diluted Earnings per Share were USD 0.32 against USD 0.10.
  • Tests accessioned reached about 207,000 against 163,000, while delivered and billable tests were about 206,000 against 165,000.
  • Cash and equivalents were USD 561.5 million at September 30, 2026, compared with USD 496.0 million at year-end.

Volume and Pricing Drive a 47% Revenue Rise

BillionToOne (NASDAQ:BLLN) filed its third-quarter report on November 4, 2026. Revenue of USD 122.98 million compared with USD 83.52 million a year earlier. Gross Profit rose to USD 87.1 million from USD 58.4 million, a gross Margin of about 70.9% against 69.9% (calculated). Management says revenue depends on tests ordered and average selling price, with in-network status improving payer reimbursement as Volume grows. Revenue related to services delivered in prior periods was USD 7.6 million against USD 3.7 million, a reminder that reimbursement adjustments can add to a quarter. Over 90% of nine-month revenue came from third-party payers. The company, a molecular diagnostics firm built on single-molecule sequencing, sells prenatal tests such as UNITY and Northstar oncology tests.

Profit Grows Slower Than Spending

Operating income was USD 11.0 million against USD 9.6 million, as Research and Development expense rose to USD 20.2 million from USD 13.0 million and selling, general and administrative expense to USD 55.9 million from USD 35.8 million. Interest income of USD 4.9 million and a USD 1.5 million Fair Value gain on a term Loan lifted Net Income to USD 17.4 million. For nine months, revenue was USD 340.8 million against USD 209.1 million, Operating Income was USD 34.4 million against USD 5.7 million, net income USD 43.4 million and diluted EPS USD 0.81. Stock-based compensation was USD 24.4 million over nine months against USD 9.6 million.

Capacity Plans, New Tests and Risks to Reimbursement

Product launches this year include Unity Confirm in May, a circulating fetal cell confirmation assay, and the Northstar PGx, Select CH and Origin add-ons. Operating Cash Flow was USD 37.1 million for nine months against USD 13.8 million, and the company borrowed USD 30 million. It has leased 229,000 square feet of laboratory space in Austin, expected to be occupied in 2027 and to process commercial samples in 2028, and a third Union City Facility for oncology. A tissue-free MRD test is expected to be commercially available in December 2026. Risks include dependence on payer coverage and rates, competition and the cost of building capacity ahead of demand.

Where Things Stand

Probably, but the filing shows both the strength and the cost. BillionToOne (NASDAQ:BLLN) delivered about 47% revenue growth, with test volume up about 27% (calculated), and profit expanded. Yet operating income grew far more slowly than revenue because research, selling and Stock Compensation costs rose quickly. Gross profit and operating margins both improved over nine months, and total Assets reached USD 760.5 million. Expansion in Austin and a possible MRD launch in December 2026 are catalysts. Reimbursement rates and payer coverage remain the central risk to the growth path, and the company drew USD 30 million of Debt in the nine months while holding USD 561.5 million of cash.